Actinic Keratoses Clinical Trial
Official title:
A Multicenter, Double-Blind, Randomized, Parallel Group, Vehicle-Controlled Study to Determine the Clinical Equivalence of a Generic Imiquimod Cream, 5% and Aldara™ Cream in Subjects With Actinic Keratosis
At the end of the study, safety and efficacy outcome measures will be compared to determine a) if dosing with Generic Imiquimod cream, 5% is therapeutically equivalent to the currently marketed Aldara (imiquimod) cream, 5% and b) if both imiquimod 5% creams are superior in comparison to the Vehicle cream.
A nationwide, multicenter, double-blind, vehicle-controlled parallel group comparison study
of a Generic Imiquimod cream, 5% (Actavis Mid-Atlantic LLC) and currently marketed Aldara
(imiquimod) cream, 5% (distributed by Graceway Pharmaceuticals, LLC) was conducted in
subjects with actinic keratoses (AKs) on the face and/or anterior scalp in order to evaluate
the therapeutic equivalence of these two active treatments and to establish superiority of
the efficacy of these two products over a Vehicle cream. Subjects were randomized to one of
three treatment groups on a 2:2:1 basis as follows: (1) Generic Imiquimod cream, 5%, (2)
Aldara (imiquimod) cream, 5%, and (3) Vehicle cream. The duration of treatment was 16 weeks
(± 7 days).
The primary efficacy endpoint was the proportion of subjects in each treatment group with
Complete Clearance (having no clinically visible actinic keratosis lesions in the 25 cm2
contiguous treatment area at the 8-week post-treatment visit) of AK lesions. The secondary
efficacy endpoints were the Partial Clearance rates, defined as the proportion of subjects
with at least a 75% reduction in the number of AK lesions counted at Baseline at the
end-of-treatment visit (Week 16, EOT) and at the 8 weeks post-treatment visit/test-of-cure
(Week 24, TOC), and the proportion of subjects with Complete Clearance of AK lesions at the
end-of-treatment (Week 16, EOT) visit.
A 90% Wald's confidence interval with Yate's continuity correction was constructed around the
difference between the proportions of subjects with Complete Clearance of AK lesions in the
active treatments (Generic Imiquimod minus Aldara) to evaluate therapeutic equivalence in the
primary efficacy analyses. Two-sided, continuity-corrected statistics were used to evaluate
the superiority of each active treatment's Complete Clearance rate over that of the Vehicle
treatment. The therapeutic comparability evaluations in the per-protocol (PP) population were
considered primary while those in the intent-to-treat (ITT) population were considered
supportive. The superiority comparisons in the ITT population were considered primary while
those in the PP population were considered supportive. If the 90% confidence interval (CI)
around the difference between the Generic Imiquimod and Aldara Complete Clearance rates in
the PP population were contained within the interval 0.20 to +0.20, and each of these rates
was greater than, and statistically different (p<0.05) from, the Vehicle rate in the ITT
population, then Generic Imiquimod and Aldara were considered to be therapeutically
equivalent.
Secondary efficacy analyses were conducted on the proportion of subjects in each treatment
group with Complete Clearance of AK lesions at the Week 16, EOT visit as well as evaluation
of the Partial Clearance of AK lesions at both the EOT and TOC visits. The results at both
the EOT visit (Week 16) and those at 8 weeks post-treatment (Week 24, TOC) were statistically
analyzed by the same methods described for the primary efficacy variable.
Both EOT and TOC analyses were conducted in the ITT population. The TOC analysis was
conducted in the PP population and the EOT analysis was conducted in the EOT PP population.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03575780 -
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
|
Phase 1 | |
| Completed |
NCT04085367 -
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
|
Phase 3 | |
| Completed |
NCT05937529 -
Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis
|
N/A | |
| Completed |
NCT02520700 -
A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses
|
N/A | |
| Terminated |
NCT01538901 -
Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients
|
Phase 4 | |
| Completed |
NCT01354717 -
Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo
|
Phase 3 | |
| Completed |
NCT00742391 -
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
|
Phase 3 | |
| Completed |
NCT03285477 -
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
|
Phase 3 | |
| Suspended |
NCT03963102 -
Duration of Ameluz Application in Acral Actinic Keratoses Response
|
Phase 4 | |
| Not yet recruiting |
NCT05923060 -
Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses
|
Phase 2 | |
| Withdrawn |
NCT06026358 -
Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands
|
Phase 4 | |
| Completed |
NCT02622594 -
Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times
|
Phase 4 | |
| Completed |
NCT00774787 -
Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
|
Phase 4 | |
| Completed |
NCT00786994 -
The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
|
Phase 2 | |
| Completed |
NCT00544258 -
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
|
Phase 1 | |
| Completed |
NCT04024579 -
Treatment of Actinic Keratosis With 5% KOH Solution
|
||
| Completed |
NCT04843553 -
Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients
|
Early Phase 1 | |
| Completed |
NCT03315286 -
Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
|
N/A | |
| Completed |
NCT03279328 -
Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents
|
Phase 4 | |
| Completed |
NCT02062853 -
Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video
|
N/A |